Biocept, Inc.

NasdaqCM:BIOC 株式レポート

時価総額:US$2.7m

Biocept マネジメント

マネジメント 基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Antonino Morales

最高経営責任者

US$781.6k

報酬総額

CEO給与比率46.8%
CEO在任期間less than a year
CEOの所有権n/a
経営陣の平均在職期間3.9yrs
取締役会の平均在任期間6.1yrs

経営陣の近況

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19
Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03
Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13
Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Jan 26
We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Dec 22
Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Nov 20

Biocept +4% on COVID-19 testing update

Nov 12

CEO報酬分析

Biocept の収益と比較して、Antonino Morales の報酬はどのように変化したか?
日付総報酬給与会社業績
Jun 30 2023n/an/a

-US$31m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$782kUS$366k

-US$32m

Sep 30 2022n/an/a

-US$25m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$8m

Dec 31 2021US$57kn/a

-US$3m

報酬と市場: Antoninoの 総報酬 ($USD 781.63K ) は、 US市場 ($USD 645.01K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Antoninoの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Antonino Morales (67 yo)

less than a year

在職期間

US$781,631

報酬

Mr. Antonino Morales serves as Director of Biocept, Inc., since July 20, 2021 and served as its Interim Chief Financial Officer since February 15, 2022 until June 21, 2023 and serves as its Chief Executive...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Antonino Morales
CEO, President & Directorless than a yearUS$781.63kデータなし
Darrell Taylor
Chief Legal Officer1.7yrsUS$773.28k0%
$ 0
Soon Hahn
Founder26.8yrsデータなしデータなし
Rob Walsh
VP & Controllerless than a yearデータなしデータなし
Philippe Marchand
Chief Operating Officer1.6yrsデータなしデータなし
Pavel Tsinberg
Director of Technology Development6.1yrsデータなしデータなし
David Moskowitz
Vice President of Strategy & Corporate Communications7yrsデータなしデータなし
Veena Singh
Senior Medical Director8.8yrsUS$577.58kデータなし

3.9yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: BIOCの経営陣は 経験豊富 であると考えられます ( 3.9年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Antonino Morales
CEO, President & Director2.3yrsUS$781.63kデータなし
Ivor Royston
Independent Director13.8yrsUS$65.21k0.000080%
$ 2.1
Linda Rubinstein
Independent Director2.3yrsUS$57.26k0%
$ 0
Quyen Dao-Haddock
Independent Directorless than a yearUS$13.32k0%
$ 0
Marsha Chandler
Independent Vice Chairman of the Board9.9yrsUS$70.21k0.000040%
$ 1.1
Fred Hirsch
Member of Clinical Advisory Boardno dataデータなしデータなし
Bruce Gerhardt
Independent Chairman of the Board13yrsUS$67.71k0.00057%
$ 15.3

6.1yrs

平均在職期間

72yo

平均年齢

経験豊富なボード: BIOCの 取締役会経験豊富 であると考えられます ( 6.1年の平均在任期間)。